Venous Leg Ulcers (Crural ulcer) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Venous leg ulcers develop when persistently high blood pressure in the veins of the legs (venous hypertension) causes damage to the skin, which eventually breaks down and forms an ulcer. Symptoms include swollen ankles filled with fluid that temporarily hold the imprint of finger when pressed, discoloration and darkening of skin around the ulcer, hardened skin around the ulcer, which may make leg feel hard and resemble the shape of an upside-down champagne bottle, and small, smooth areas of white skin, which may have tiny red spots.
The venous leg ulcers drugs in development market report provides an overview of the Venous Leg Ulcers (Crural Ulcer) pipeline landscape. The report provides comprehensive information on the therapeutics under development for venous leg ulcers, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for venous leg ulcers and features dormant and discontinued projects.
What are the targets of the venous leg ulcers pipeline drugs market?
The targets of the venous leg ulcers pipeline drugs market are Fibroblast Growth Factor Receptor 1, Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase, ATP Binding Cassette Sub Family B Member 5, Type Lectin Domain Family 7 Member A, Fibroblast Growth Factor 2, Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha, Interleukin 4, Interleukin 6, Interleukin 8, Macrophage Colony Stimulating Factor 1, Peptidoglycan, Toll Like Receptor 2, and Vascular Endothelial Growth Factor).
Venous leg ulcers pipeline drugs market, by targets
For more target insights, download a free report sample
What are the mechanisms of action of the venous leg ulcers pipeline drugs market?
The mechanisms of action of the venous leg ulcers pipeline drugs market are Fibroblast Growth Factor Receptor 1 Agonist, Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase Activator, Fibroblast Growth Factor 2 Activator, Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha Agonist, Interleukin 4 Activator, Interleukin 6 Inhibitor, Interleukin 8 Inhibitor, Macrophage Colony Stimulating Factor 1 Activator, Peptidoglycan Inhibitor, Toll Like Receptor 2 Agonist, and Vascular Endothelial Growth Factor Activator.
Venous leg ulcers pipeline drugs market, by mechanisms of action
For more mechanisms of action insights, download a free report sample
What are the routes of administration in the venous leg ulcers pipeline drugs market?
The routes of administration in the venous leg ulcers pipeline drugs market are topical, subcutaneous, and intralesional.
Venous leg ulcers pipeline drugs market, by routes of administration
For more routes of administration insights, download a free report sample
What are the molecule types in the venous leg ulcers pipeline drugs market?
The molecule types in the venous leg ulcers pipeline drugs market are small molecule, recombinant protein, cell therapy, enzyme, biologic, polysaccharide, and synthetic peptide.
Venous leg ulcers pipeline drugs market, by molecule types
For more molecule types insights, download a free report sample
Which are the key companies in the venous leg ulcers pipeline drugs market?
Some of the key companies in the venous leg ulcers pipeline drugs market are Aurealis Therapeutics AG, CytoTools AG, Energenesis Biomedical Co Ltd, GangaGen Biotechnologies Pvt Ltd, Hypo-Stream Ltd, Mallinckrodt Plc, MediWound Ltd, NovaLead Pharma Pvt Ltd, Promore Pharma AB, QBiotics Group Ltd, Reponex Pharmaceuticals AS, RHEACELL GmbH & Co KG, and Tissue Repair Pty Ltd.
Venous leg ulcers pipeline drugs market, by key companies
To know more about key companies, download a free report sample
Market report scope
| Targets | Fibroblast Growth Factor Receptor 1, Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase, ATP Binding Cassette Sub Family B Member 5, Type Lectin Domain Family 7 Member A, Fibroblast Growth Factor 2, Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha, Interleukin 4, Interleukin 6, Interleukin 8, Macrophage Colony Stimulating Factor 1, Peptidoglycan, Toll Like Receptor 2, and Vascular Endothelial Growth Factor) |
| Mechanisms of Action | Fibroblast Growth Factor Receptor 1 Agonist, Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase Activator, Fibroblast Growth Factor 2 Activator, Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha Agonist, Interleukin 4 Activator, Interleukin 6 Inhibitor, Interleukin 8 Inhibitor, Macrophage Colony Stimulating Factor 1 Activator, Peptidoglycan Inhibitor, Toll Like Receptor 2 Agonist, and Vascular Endothelial Growth Factor Activator |
| Routes of Administration | Topical, Subcutaneous, and Intralesional |
| Molecule Types | Small Molecule, Recombinant Protein, Cell Therapy, Enzyme, Biologic, Polysaccharide, and Synthetic Peptide |
| Key Companies | Aurealis Therapeutics AG, CytoTools AG, Energenesis Biomedical Co Ltd, GangaGen Biotechnologies Pvt Ltd, Hypo-Stream Ltd, Mallinckrodt Plc, MediWound Ltd, NovaLead Pharma Pvt Ltd, Promore Pharma AB, QBiotics Group Ltd, Reponex Pharmaceuticals AS, RHEACELL GmbH & Co KG, and Tissue Repair Pty Ltd |
This report provides:
- A snapshot of the global therapeutic landscape of Venous Leg Ulcers (Crural Ulcer) (Dermatology).
- Reviews of pipeline therapeutics for Venous Leg Ulcers (Crural Ulcer) (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- Descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- Key companies involved in Venous Leg Ulcers (Crural Ulcer) (Dermatology) therapeutics and enlists all their major and minor projects.
- Evaluation of Venous Leg Ulcers (Crural Ulcer) (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- All the dormant and discontinued pipeline projects.
- Reviews of the latest news related to pipeline therapeutics for Venous Leg Ulcers (Dermatology).
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Venous Leg Ulcers (Crural Ulcer) (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Venous Leg Ulcers (Crural Ulcer) (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline.
CytoTools AG
Energenesis Biomedical Co Ltd
GangaGen Biotechnologies Pvt Ltd
Hypo-Stream Ltd
Mallinckrodt Plc
MediWound Ltd
NovaLead Pharma Pvt Ltd
Promore Pharma AB
QBiotics Group Ltd
Reponex Pharmaceuticals AS
RHEACELL GmbH & Co KG
Tissue Repair Pty Ltd
Venturis Therapeutics Inc
Zhittya Genesis Medicine Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the targets of the venous leg ulcers pipeline drugs market?
The targets of the venous leg ulcers pipeline drugs market are Fibroblast Growth Factor Receptor 1, Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase, ATP Binding Cassette Sub Family B Member 5, Type Lectin Domain Family 7 Member A, Fibroblast Growth Factor 2, Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha, Interleukin 4, Interleukin 6, Interleukin 8, Macrophage Colony Stimulating Factor 1, Peptidoglycan, Toll Like Receptor 2, and Vascular Endothelial Growth Factor).
-
What are the mechanisms of action of the venous leg ulcers pipeline drugs market?
The mechanisms of action of the venous leg ulcers pipeline drugs market are Fibroblast Growth Factor Receptor 1 Agonist, Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase Activator, Fibroblast Growth Factor 2 Activator, Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha Agonist, Interleukin 4 Activator, Interleukin 6 Inhibitor, Interleukin 8 Inhibitor, Macrophage Colony Stimulating Factor 1 Activator, Peptidoglycan Inhibitor, Toll Like Receptor 2 Agonist, and Vascular Endothelial Growth Factor Activator.
-
What are the routes of administration in the venous leg ulcers pipeline drugs market?
The routes of administration in the venous leg ulcers pipeline drugs market are topical, subcutaneous, and intralesional.
-
What are the molecule types in the venous leg ulcers pipeline drugs market?
The molecule types in the venous leg ulcers pipeline drugs market are small molecule, recombinant protein, cell therapy, enzyme, biologic, polysaccharide, and synthetic peptide.
-
Which are the key companies in the venous leg ulcers pipeline drugs market?
Some of the key companies in the venous leg ulcers pipeline drugs market are Aurealis Therapeutics AG, CytoTools AG, Energenesis Biomedical Co Ltd, GangaGen Biotechnologies Pvt Ltd, Hypo-Stream Ltd, Mallinckrodt Plc, MediWound Ltd, NovaLead Pharma Pvt Ltd, Promore Pharma AB, QBiotics Group Ltd, Reponex Pharmaceuticals AS, RHEACELL GmbH & Co KG, and Tissue Repair Pty Ltd.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Related reports
View more Dermatology reports